Important novel aspects of the study include its longitudinal design and the integration of genetic analyses into the conceptual framework of Alzheimer’s disease staging using Aβ and tau biomarkers. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.